
Precigen (PGEN) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
1.3M
Gross Profit
241.0K
17.97%
Operating Income
-22.6M
-1,685.01%
Net Income
-54.2M
-4,038.26%
EPS (Diluted)
$-0.18
Balance Sheet Metrics
Total Assets
128.8M
Total Liabilities
142.8M
Shareholders Equity
-14.1M
Cash Flow Metrics
Operating Cash Flow
-49.4M
Free Cash Flow
-16.9M
Revenue & Profitability Trend
Precigen Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 3.9M | 6.2M | 26.9M | 14.3M | 103.2M |
Cost of Goods Sold | 4.3M | 6.1M | 6.3M | 5.7M | 55.5M |
Gross Profit | -342.0K | 106.0K | 20.6M | 8.5M | 47.7M |
Gross Margin % | -8.7% | 1.7% | 76.4% | 59.7% | 46.2% |
Operating Expenses | |||||
Research & Development | 53.1M | 48.6M | 47.2M | 47.9M | 41.6M |
Selling, General & Administrative | 41.3M | 40.4M | 48.0M | 52.0M | 91.7M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 94.4M | 89.0M | 95.2M | 99.9M | 133.3M |
Operating Income | -94.7M | -88.9M | -74.6M | -91.4M | -85.7M |
Operating Margin % | -2,412.9% | -1,428.5% | -277.3% | -640.7% | -83.0% |
Non-Operating Items | |||||
Interest Income | 1.4M | 3.2M | 133.0K | 171.0K | 2.5M |
Interest Expense | 6.0K | 468.0K | 6.8M | 18.8M | 18.4M |
Other Non-Operating Income | -34.7M | -10.2M | 1.3M | -978.0K | -2.2M |
Pre-tax Income | -128.0M | -96.4M | -80.0M | -111.0M | -103.9M |
Income Tax | -1.8M | -458.0K | -189.0K | -160.0K | -82.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -126.2M | -95.9M | 28.3M | -92.2M | -170.5M |
Net Margin % | -3,216.2% | -1,540.6% | 105.2% | -646.0% | -165.3% |
Key Metrics | |||||
EBITDA | -83.2M | -78.4M | -61.3M | -77.9M | -67.0M |
EPS (Basic) | $-0.47 | $-0.39 | $0.14 | $-0.47 | $-1.02 |
EPS (Diluted) | $-0.47 | $-0.39 | $0.14 | $-0.47 | $-1.02 |
Basic Shares Outstanding | 267727426 | 244536221 | 200360821 | 197759900 | 167065539 |
Diluted Shares Outstanding | 267727426 | 244536221 | 200360821 | 197759900 | 167065539 |
Income Statement Trend
Precigen Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 29.5M | 7.6M | 4.9M | 36.4M | 51.8M |
Short-term Investments | 68.4M | 55.3M | 51.1M | 72.2M | 48.3M |
Accounts Receivable | 926.0K | 902.0K | 978.0K | 1.3M | 16.5M |
Inventory | - | - | 287.0K | 326.0K | 11.4M |
Other Current Assets | 3.3M | 4.3M | 5.1M | 5.5M | 7.2M |
Total Current Assets | 102.4M | 68.8M | 118.2M | 156.6M | 148.9M |
Non-Current Assets | |||||
Property, Plant & Equipment | 21.8M | 25.7M | 26.1M | 26.8M | 40.5M |
Goodwill | 42.7M | 93.9M | 118.3M | 127.4M | 174.1M |
Intangible Assets | 4.5M | 40.7M | 44.5M | 52.3M | 65.4M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 459.0K | 846.0K | 1.1M | 46.3M | 2.5M |
Total Non-Current Assets | 42.9M | 82.3M | 97.8M | 203.2M | 165.6M |
Total Assets | 145.3M | 151.0M | 216.0M | 359.9M | 314.6M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 3.5M | 1.7M | 4.1M | 3.1M | 4.6M |
Short-term Debt | 956.0K | 1.2M | 44.4M | 1.4M | 3.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | 12.9M | 14.0M |
Total Current Liabilities | 21.5M | 23.0M | 78.6M | 34.6M | 42.1M |
Non-Current Liabilities | |||||
Long-term Debt | 4.5M | 5.9M | 7.0M | 188.6M | 179.3M |
Deferred Tax Liabilities | 0 | 1.8M | 2.3M | 2.5M | 2.9M |
Other Non-Current Liabilities | - | - | - | 50.0K | 100.0K |
Total Non-Current Liabilities | 85.2M | 9.6M | 11.1M | 217.9M | 205.3M |
Total Liabilities | 106.8M | 32.5M | 89.7M | 252.5M | 247.4M |
Equity | |||||
Common Stock | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -2.1B | -2.0B | -1.9B | -1.9B | -1.8B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 38.5M | 118.5M | 126.3M | 107.3M | 67.2M |
Key Metrics | |||||
Total Debt | 5.5M | 7.1M | 51.4M | 190.1M | 182.3M |
Working Capital | 80.9M | 45.8M | 39.5M | 122.0M | 106.8M |
Balance Sheet Composition
Precigen Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -126.2M | -95.9M | 28.3M | -92.2M | -170.5M |
Depreciation & Amortization | 4.5M | 6.7M | 10.8M | 13.8M | 17.5M |
Stock-Based Compensation | 9.5M | 9.9M | 10.2M | 13.9M | 18.4M |
Working Capital Changes | 5.4M | 15.5M | -34.5M | -3.2M | -17.1M |
Operating Cash Flow | -109.7M | -77.4M | -65.3M | -61.3M | -129.3M |
Investing Activities | |||||
Capital Expenditures | -8.6M | -1.5M | -4.9M | -7.2M | -7.5M |
Acquisitions | - | - | - | 0 | 0 |
Investment Purchases | -187.2M | -185.0M | 0 | -174.2M | -171.4M |
Investment Sales | 175.0M | 183.4M | 68.4M | 100.2M | 133.0M |
Investing Cash Flow | -20.7M | -3.1M | 64.1M | -74.5M | -36.5M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | 0 | 0 |
Debt Repayment | 0 | -43.2M | -155.3M | -466.0K | -12.4M |
Financing Cash Flow | 110.2M | 29.6M | -155.9M | 120.6M | 20.7M |
Free Cash Flow | -76.8M | -68.5M | -70.0M | -63.0M | -84.5M |
Net Change in Cash | -20.2M | -50.9M | -157.1M | -15.3M | -145.1M |
Cash Flow Trend
Precigen Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-8.89
Forward P/E
-16.55
Price to Book
-33.69
Price to Sales
249.91
PEG Ratio
0.15
Profitability Ratios
Profit Margin
-8.71%
Operating Margin
-3,254.32%
Return on Equity
-668.03%
Return on Assets
-67.44%
Financial Health
Current Ratio
2.71
Debt to Equity
-0.14
Beta
1.87
Per Share Data
EPS (TTM)
$-0.41
Book Value per Share
$-0.12
Revenue per Share
$0.02
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
pgen | 1.1B | -8.89 | -33.69 | -668.03% | -8.71% | -0.14 |
Vertex | 101.3B | 28.08 | 5.90 | 22.77% | 31.86% | 8.89 |
Regeneron | 63.6B | 15.12 | 2.09 | 15.34% | 31.37% | 9.04 |
Sarepta Therapeutics | 2.0B | 19.98 | 1.46 | -4.76% | -2.34% | 100.51 |
Adaptive | 2.0B | -12.04 | 11.01 | -57.60% | -59.07% | 121.39 |
Arcutis | 1.9B | -13.78 | 13.78 | -57.33% | -35.40% | 79.27 |
Financial data is updated regularly. All figures are in the company's reporting currency.